CR20110099A - Pirrolidina-2-carboxamidas sustituidas - Google Patents
Pirrolidina-2-carboxamidas sustituidasInfo
- Publication number
- CR20110099A CR20110099A CR20110099A CR20110099A CR20110099A CR 20110099 A CR20110099 A CR 20110099A CR 20110099 A CR20110099 A CR 20110099A CR 20110099 A CR20110099 A CR 20110099A CR 20110099 A CR20110099 A CR 20110099A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pirrolidina
- carboxamids
- substituted
- compounds
- esters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan compuestos de la fórmula, en la que X, Y, R1, R2, R3, R3, R4, R5, R6 y R7 tienen los significados aquí descritos y enantiómeros y sales y ésteres farmacéuticamente aceptables de los mismos. Estos compuestos son útiles como agentes anticancerosos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9788408P | 2008-09-18 | 2008-09-18 | |
US22563309P | 2009-07-15 | 2009-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20110099A true CR20110099A (es) | 2011-04-04 |
Family
ID=41402151
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20110099A CR20110099A (es) | 2008-09-18 | 2011-02-21 | Pirrolidina-2-carboxamidas sustituidas |
Country Status (30)
Country | Link |
---|---|
US (1) | US20100075948A1 (es) |
EP (1) | EP2340021B1 (es) |
JP (1) | JP5658157B2 (es) |
KR (1) | KR101380013B1 (es) |
CN (1) | CN102159207B (es) |
AR (1) | AR073598A1 (es) |
AU (1) | AU2009294673B2 (es) |
BR (1) | BRPI0919325A2 (es) |
CA (1) | CA2734363C (es) |
CL (1) | CL2011000589A1 (es) |
CO (1) | CO6361910A2 (es) |
CR (1) | CR20110099A (es) |
DK (1) | DK2340021T3 (es) |
EC (1) | ECSP11010898A (es) |
ES (1) | ES2398342T3 (es) |
HK (1) | HK1160399A1 (es) |
HR (1) | HRP20130047T1 (es) |
IL (1) | IL211167A0 (es) |
MA (1) | MA32711B1 (es) |
MX (1) | MX2011002976A (es) |
MY (1) | MY160424A (es) |
NZ (1) | NZ591024A (es) |
PE (1) | PE20110367A1 (es) |
PL (1) | PL2340021T3 (es) |
PT (1) | PT2340021E (es) |
RS (1) | RS52660B (es) |
RU (1) | RU2506257C2 (es) |
TW (1) | TWI367207B (es) |
WO (1) | WO2010031713A1 (es) |
ZA (1) | ZA201101740B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
US8354444B2 (en) | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
US8017607B2 (en) | 2009-10-14 | 2011-09-13 | Hoffmann-La Roche Inc. | N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions |
US20110118283A1 (en) * | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
US20120046306A1 (en) * | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
CN101898998B (zh) * | 2010-08-25 | 2012-09-19 | 武汉武药科技有限公司 | 一种盐酸替罗非班中间体的制备方法 |
US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
WO2012076513A1 (en) * | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
MY172862A (en) | 2011-03-10 | 2019-12-13 | Daiichi Sankyo Co Ltd | Dispiropyrrolidine derivatives |
US9376425B2 (en) | 2011-09-27 | 2016-06-28 | Amgen, Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
WO2013178570A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
RU2016101514A (ru) | 2013-07-03 | 2017-08-08 | Ф. Хоффманн-Ля Рош Аг | ЭКСПРЕССИЯ мРНК ГЕНОВ ДЛЯ ПЕРСОНАЛИЗАЦИИ ПРОТИВООПУХОЛЕВОЙ ТЕРАПИИ ПАЦИЕНТОВ АНТАГОНИСТОМ MDM2 |
KR102389552B1 (ko) | 2014-04-17 | 2022-04-22 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Mdm2 저해제 및 이 저해제를 사용하는 치료 방법 |
CN107427501B (zh) | 2015-02-20 | 2023-12-01 | 第一三共株式会社 | 通过联合使用治疗癌症的方法 |
US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
WO2018074387A1 (ja) | 2016-10-17 | 2018-04-26 | 第一三共株式会社 | Mdm2阻害剤とdnaメチルトランスフェラーゼ阻害剤との併用治療法 |
KR102122469B1 (ko) * | 2016-11-01 | 2020-06-12 | 주식회사 엘지화학 | 변성 공액디엔계 중합체 및 이의 제조방법 |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US10647661B2 (en) | 2017-07-11 | 2020-05-12 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
WO2019213106A1 (en) | 2018-04-30 | 2019-11-07 | Teva Pharmaceuticals International Gmbh | Solid state forms of idasanutlin |
EP3860654A1 (en) | 2018-10-03 | 2021-08-11 | Rijksuniversiteit Groningen | Photoresponsive nutlin derivatives and uses thereof |
EP4069691A1 (en) | 2019-12-06 | 2022-10-12 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofurans as modulators of sodium channels |
AU2022284886A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7491394B2 (en) * | 2001-02-15 | 2009-02-17 | The Board Of Trustees Of The University Of Illinois | Cytotoxic factors for modulating cell death |
TW200404796A (en) * | 2002-08-19 | 2004-04-01 | Ono Pharmaceutical Co | Nitrogen-containing compound |
EA014445B1 (ru) * | 2005-02-22 | 2010-12-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Низкомолекулярные ингибиторы mdm2 и их применения |
CA2656398A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
-
2009
- 2009-09-08 RU RU2011115111/04A patent/RU2506257C2/ru active
- 2009-09-08 MX MX2011002976A patent/MX2011002976A/es active IP Right Grant
- 2009-09-08 JP JP2011527289A patent/JP5658157B2/ja active Active
- 2009-09-08 PE PE2011000600A patent/PE20110367A1/es active IP Right Grant
- 2009-09-08 MY MYPI2011001187A patent/MY160424A/en unknown
- 2009-09-08 AU AU2009294673A patent/AU2009294673B2/en active Active
- 2009-09-08 EP EP09782745A patent/EP2340021B1/en active Active
- 2009-09-08 NZ NZ591024A patent/NZ591024A/xx unknown
- 2009-09-08 RS RS20130030A patent/RS52660B/en unknown
- 2009-09-08 CN CN200980136886.XA patent/CN102159207B/zh active Active
- 2009-09-08 ES ES09782745T patent/ES2398342T3/es active Active
- 2009-09-08 PT PT97827455T patent/PT2340021E/pt unknown
- 2009-09-08 KR KR1020117006169A patent/KR101380013B1/ko active IP Right Grant
- 2009-09-08 BR BRPI0919325-1A patent/BRPI0919325A2/pt not_active Application Discontinuation
- 2009-09-08 DK DK09782745.5T patent/DK2340021T3/da active
- 2009-09-08 PL PL09782745T patent/PL2340021T3/pl unknown
- 2009-09-08 CA CA2734363A patent/CA2734363C/en active Active
- 2009-09-08 WO PCT/EP2009/061610 patent/WO2010031713A1/en active Application Filing
- 2009-09-10 US US12/556,656 patent/US20100075948A1/en not_active Abandoned
- 2009-09-15 TW TW098131076A patent/TWI367207B/zh active
- 2009-09-16 AR ARP090103554A patent/AR073598A1/es unknown
-
2011
- 2011-02-10 CO CO11015847A patent/CO6361910A2/es active IP Right Grant
- 2011-02-10 IL IL211167A patent/IL211167A0/en active IP Right Grant
- 2011-02-21 CR CR20110099A patent/CR20110099A/es unknown
- 2011-03-07 ZA ZA2011/01740A patent/ZA201101740B/en unknown
- 2011-03-15 EC EC2011010898A patent/ECSP11010898A/es unknown
- 2011-03-18 CL CL2011000589A patent/CL2011000589A1/es unknown
- 2011-04-13 MA MA33771A patent/MA32711B1/fr unknown
-
2012
- 2012-02-02 HK HK12100945.2A patent/HK1160399A1/xx unknown
-
2013
- 2013-01-21 HR HRP20130047AT patent/HRP20130047T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20110099A (es) | Pirrolidina-2-carboxamidas sustituidas | |
CR20120410A (es) | Pirrolidina-2-carboxamidas sustituidas | |
ECSP12011945A (es) | Espiroindolinona-pirrolidinas | |
ECSP12011625A (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
ECSP14013245A (es) | Nuevos derivados dihidroquinolina-2-ona | |
IN2012DN02487A (es) | ||
BRPI0821255A2 (pt) | Derivados de espiroindolinona | |
MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
ATE524470T1 (de) | Spiroindolinonderivate als antikrebsmittel | |
UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
ATE495176T1 (de) | Spiroindolinon-derivate | |
CO6430425A2 (es) | Compuestos en calidad de antagonistas de bradiquinina b1 | |
NI201100096A (es) | Lactamas como inhibidores de beta secretasa. | |
UY32553A (es) | Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos | |
BRPI0909333A2 (pt) | derivado de espiroindolinona | |
CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
CR11759A (es) | Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas | |
DOP2012000078A (es) | Derivados de espirolactama y usos de los mismos | |
ECSP11011217A (es) | Microbiocidas nuevos. | |
HN2009001330A (es) | Compuestos novedosos activos como antagonistas de receptore muscarinico | |
CU20130065A7 (es) | Derivados de indol | |
CO6602120A2 (es) | Pirrolidina-25-carboxamidas sustituidas | |
UA103497C2 (en) | Substituted pyrrolidine-2-carboxamides | |
CY1113810T1 (el) | Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια |